The effect of small-molecular-weight heparin added to chemotherapy on survival in XXXX - A retrospective analysis.

@entity5 @entity1 @entity151 @entity1349
Aims and Background: @entity151 ( @entity151 ) is a chemotherapy-responsive @entity5 and associated with alterations in the coagulation system. Addition of low-molecular-weight heparin (LMWH) to combination chemotherapy (CT) had resulted in increase in survival. The present retrospective trial was designed to determine whether the duration of dalteparin usage has an effect on progression and survival. Materials and Methods: The medical records of 67 @entity1 with @entity151 who were given cisplatin-etoposide and concomitant LMWH (dalteparin) was evaluated retrospectively. Results: Median follow-up of @entity1 was 11.3 months. Outcome: 10.6% complete response, 3.0% good partial response, 36.4% partial response, 10.6% stable disease, and 39.4% progressive disease. Side-effects were seen in 40.3% of the @entity1 . Median dalteparin duration was 6,1 months. According the duration of dalteparin @entity1 were grouped in three: who took dalteparin less than 4 months (Group A), 4-6 months (Group B) and more than 6 months (Group C). Mean @entity1349 ( @entity1349 ) in Group A was 6.5 months, in Group B 11.8 months, and Group C 14.6 months. Mean @entity1349 in Group B and C were statistically significantly (P < 0.001) longer than Group A, between Group B and C there was not any significant difference (P = 0.037). Mean progression free survival (PFS) was 9 months. Conclusions: The CT plus LMWH minimum 4 months long is well-tolerable, and may improve PFS and @entity1349 in @entity1 with @entity151 . For treatment of @entity1 with @entity151 CT plus LMWH may be considered as effective future-therapy, and further multi-centre randomised prospective clinical trials must be done to determine the new standard treatment approach for @entity151 .
